Mounjaro Dosages: All 6 Doses Explained, with Titration Schedule and A1C Effects

Key Takeaways

• Mounjaro comes in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all delivered as once-weekly subcutaneous injections.
• The standard titration schedule increases by 2.5 mg every 4 weeks. The 2.5 mg dose is a starting dose, not a maintenance dose.
• The minimum effective maintenance dose for type 2 diabetes is 5 mg weekly. Most patients reach 5 mg, 10 mg, or 15 mg as their maintenance.
• A1C reduction averages about 1.9% on 5 mg and 2.4% on 15 mg in trials (SURPASS program; Frias et al., NEJM 2021).
• The pen is single-dose, comes in a four-pack (one month supply at the dose printed on the box), and ships pre-filled.

Direct answer (40-60 words)

Mounjaro is dosed in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, delivered once weekly. The 2.5 mg is a starting dose only. Patients move up by 2.5 mg every 4 weeks, with maintenance typically at 5, 10, or 15 mg. A1C reduction ranges from about 1.9% to 2.4% across maintenance doses.

Table of contents

1. The 30-second answer
2. The full Mounjaro dose list with pen colors
3. The standard titration schedule
4. Why 2.5 mg isn't a maintenance dose
5. A1C results by dose, from the SURPASS trials
6. Weight loss results by dose
7. How providers decide where to stop titrating
8. What to do if you can't tolerate the next dose up
9. Missed doses and dose changes
10. Side effects, by dose
11. FAQ
12. Sources
13. Footer disclaimers

The full Mounjaro dose list with pen colors

Mounjaro is manufactured by Eli Lilly and sold in six dose strengths. Each pen is a single-use auto-injector. A box contains four pens (a 4-week supply at the labeled dose).

All six doses are delivered in the same volume of fluid (0.5 mL). The drug concentration changes between pens, so don't try to estimate dose by looking at the volume in the pen. The dose is printed on the pen and on the box.

The pen colors are intended for quick recognition and dispensing accuracy. Color schemes can change slightly between batches and packaging revisions. Always confirm the dose printed on the carton, not the color.

The standard titration schedule

Per FDA prescribing information, Mounjaro titration follows a fixed cadence: 4 weeks at the starting dose, then 4 weeks at each subsequent dose until the target is reached.

The fastest possible escalation to maximum (15 mg) is 20 weeks (5 months) from the first 2.5 mg injection. Many patients stop earlier, when A1C and weight goals are met or when side effects make further escalation unfavorable.

Some providers stretch the 4-week steps to 8 weeks if a patient has more nausea or GI side effects. Slower titration is acceptable. Faster titration (less than 4 weeks per dose) is not recommended in the prescribing information.

If a patient stops Mounjaro for more than 4 weeks (illness, supply gap, etc.), restarting should follow the same titration: back to 2.5 mg for 4 weeks before stepping up. This prevents the GI side-effect burst that comes with restarting at a high dose.

Why 2.5 mg isn't a maintenance dose

The 2.5 mg starting dose is intended only for tolerability. It produces some A1C and weight reduction (around 1.5% A1C drop, 5 to 6 lbs of weight loss in trials), but Eli Lilly explicitly labels it as a starting dose, not a maintenance dose. The reason is regulatory: 2.5 mg was not formally tested as a maintenance dose for diabetes treatment in the SURPASS trials.

In practice, providers can keep a patient at 2.5 mg longer than 4 weeks if needed for tolerance, but the goal is always to reach 5 mg (the lowest formally approved maintenance dose). Insurance coverage typically requires escalation to at least 5 mg for continued coverage; staying at 2.5 mg long-term may trigger prior authorization issues.

If a patient genuinely cannot tolerate 5 mg, the decision is usually between staying at 2.5 mg (off-label as maintenance, may have coverage issues) or switching to a different GLP-1 medication.

A1C results by dose, from the SURPASS trials

The SURPASS program tested Mounjaro in adults with type 2 diabetes across multiple comparator arms (placebo, semaglutide, insulin glargine, insulin degludec). The cleanest dose-response data comes from SURPASS-1 (vs placebo) and SURPASS-2 (vs semaglutide 1 mg).

A1C reduction at week 40 to 52, by dose:

Key takeaway: the A1C benefit increases modestly with each dose step. The jump from placebo to 5 mg is by far the biggest. The increase from 10 mg to 15 mg is small (about 0.1 to 0.2 A1C points).

For patients meeting their A1C goal at 5 mg or 10 mg, escalating further usually isn't worth additional side-effect risk for marginal A1C benefit. For patients above their A1C goal at 10 mg, the 12.5 mg or 15 mg step can produce additional 0.2 to 0.4% A1C reduction.

Weight loss results by dose

Weight loss is the secondary outcome that drives most Mounjaro prescriptions today, even when the FDA-approved indication is type 2 diabetes (Mounjaro for diabetes; Zepbound is the same molecule approved for weight loss).

Average weight loss in SURPASS-2 (T2D patients on metformin, 40 weeks):

Weight loss in SURMOUNT-1 (Zepbound for obesity without diabetes, 72 weeks; Jastreboff et al., NEJM 2022):

The 15 mg dose produces the largest weight loss but the gap between 10 mg and 15 mg is smaller than the gap between 5 mg and 10 mg. Many patients pursuing weight loss find that 10 mg gives them most of the benefit they'd see at 15 mg, with somewhat fewer side effects.

For patients with type 2 diabetes only (Mounjaro), weight loss tends to be smaller than in obesity-only patients (Zepbound) at the same dose. The SURPASS trials enrolled patients with average baseline BMI of about 32 to 33; SURMOUNT enrolled at average BMI 38.

How providers decide where to stop titrating

Most providers use a combination of A1C target, weight goal, and side-effect tolerance to decide where to stop the titration ladder.

For type 2 diabetes:

• A1C target met (often <7% for most adults, <6.5% for some) -> stop at current dose
• A1C still above target with manageable side effects -> escalate at the next 4-week mark
• Side effects intolerable at current dose -> hold dose or step back
• Reached 15 mg with A1C still above target -> consider adding another agent (insulin, SGLT2 inhibitor, etc.) rather than continuing to escalate

For weight loss focus (Zepbound, same active ingredient):

• Weight loss progressing at expected rate (about 1 to 2 lbs per week early on) -> hold dose; no need to escalate
• Weight loss plateauing well below goal -> consider escalation
• Side effects manageable -> proceed with escalation per standard schedule
• Side effects unmanageable -> hold or step back

A common pattern in clinical practice: patients escalate to 10 mg, find weight loss progressing well, and stay at 10 mg as a maintenance dose rather than pushing to 12.5 mg or 15 mg. The marginal benefit at higher doses is real but smaller than the benefit gained from the early steps.

What to do if you can't tolerate the next dose up

A common scenario: a patient does well on 5 mg for 4 weeks, escalates to 7.5 mg, and develops worse nausea, vomiting, or diarrhea. Options in order of preference:

1. Wait it out at the new dose for 1 to 2 weeks. Most GI side effects improve as the body adapts. If improving by week 2, continue at 7.5 mg and reassess.
2. Step back to the prior dose for 4 more weeks. If the next attempt at escalation still fails, that may be the patient's ceiling.
3. Stretch the titration to 8 weeks per step. Slower titration improves tolerability for some patients.
4. Use anti-nausea support. Ondansetron 4 mg as needed, ginger, smaller meals, avoiding fatty foods. These help many patients tolerate escalation.
5. Consider switching molecules. If multiple Mounjaro doses cause unmanageable side effects, switching to semaglutide (Ozempic, Wegovy) may help; semaglutide tends to have somewhat lower GI side-effect rates at equivalent doses.

The key principle: there's no medical urgency to reach 15 mg. Stopping at 5 mg or 10 mg with good A1C and weight outcomes is fine. The dose ladder is a tool, not a target.

Missed doses and dose changes

Missed dose, less than 4 days late: Take the missed dose as soon as you remember. Continue with the regular weekly schedule.

Missed dose, 4 days or more late: Skip the missed dose. Take the next dose on the regularly scheduled day. Don't double up.

Missed multiple doses (more than 4 weeks off): Restart at 2.5 mg with a fresh titration. The body's tolerance to GLP-1 effects fades within weeks of stopping; re-escalating without titration usually causes severe nausea.

Day-of-week change: It's safe to shift the weekly injection day by 1 to 3 days as long as the previous dose was at least 3 days before the new dose. Best to make permanent day changes during a stable maintenance dose, not during escalation.

Switching pens between fills: No special protocol needed. The pen design and injection technique are the same across all six dose strengths.

Side effects, by dose

GI side effects (nausea, vomiting, diarrhea, constipation, abdominal pain) are the most common and tend to be dose-related but with some adaptation across each step.

Nausea rates from SURPASS-1 to 5:

The dose-response is real but modest. The biggest jump in nausea risk is during the first dose change (2.5 to 5 mg) and during the early weeks of any new dose. Most patients adapt within 2 to 3 weeks.

Less common but more serious risks (similar across doses):

• Pancreatitis (rare; severe abdominal pain radiating to the back)
• Gallbladder disease (more common during rapid weight loss)
• Hypoglycemia (when combined with insulin or sulfonylureas)
• Acute kidney injury (usually from severe vomiting or diarrhea)
• Thyroid C-cell tumor risk (boxed warning, based on rodent data; contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2)

These risks don't scale dramatically with dose. The main dose-related side effects are GI.

FAQ

What are the available Mounjaro doses? Mounjaro comes in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. All are once-weekly subcutaneous injections. The 2.5 mg is a starting dose for tolerability; the others are maintenance options.

What is the starting dose for Mounjaro? The starting dose is 2.5 mg once weekly for 4 weeks. This dose is for tolerability only and is not a maintenance dose. After 4 weeks, providers escalate to 5 mg, the lowest approved maintenance dose for type 2 diabetes.

What is the maximum dose of Mounjaro? The maximum dose is 15 mg once weekly. Per SURPASS trial data, the 15 mg dose produces the largest A1C reduction and largest weight loss. Some patients reach this dose; many stop earlier because lower doses already meet their goals.

How often do you increase Mounjaro doses? The standard schedule is 4 weeks per dose, increasing by 2.5 mg per step. Some providers stretch to 8 weeks per step for better tolerability. Faster than 4 weeks is not recommended in the prescribing information.

Which Mounjaro dose is best for weight loss? For weight loss focus, the same-molecule product Zepbound is FDA-approved at 5 mg, 10 mg, and 15 mg as maintenance doses. The SURMOUNT-1 trial showed 15.0% body weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. Most patients land at 10 mg for the best benefit-tolerance balance.

Can I stay on the 2.5 mg dose long-term? Generally no. The 2.5 mg dose was studied only as a starting dose, not a maintenance dose. Insurance often won't cover long-term use at 2.5 mg. If you can't tolerate 5 mg, talk with your provider about switching molecules or extending titration time.

What happens if I miss a Mounjaro dose? If less than 4 days late, take the dose when you remember and continue your weekly schedule. If 4 or more days late, skip it and take the next dose on the regular day. If you've missed more than 4 weeks, restart at 2.5 mg with a fresh titration.

Can I jump from 5 mg straight to 10 mg? Not typically. The standard escalation goes through 7.5 mg as a bridge. Skipping the 7.5 mg step risks more severe nausea and vomiting. Providers may use the larger jump in select cases but it's off the standard schedule.

Does the 15 mg Mounjaro dose hurt more than lower doses? The volume injected is the same across all doses (0.5 mL). The drug concentration changes between pens, but injection sensation isn't notably different. Some patients report more local burning at higher concentrations; this isn't a consistent finding in trials.

How do I know which Mounjaro pen color is which dose? The color isn't reliable for ID. Always read the dose printed on the pen label and the carton. Lilly may revise color schemes over time. Confirm dose at the pharmacy and again before injection.

Is the 12.5 mg dose just a bridge or a maintenance dose? Both. 12.5 mg can be used as a bridge from 10 mg to 15 mg (4 weeks) or held as a long-term maintenance dose if A1C and weight goals are met at that step. There's nothing special about it that requires further escalation.

Why does my insurance only approve up to 10 mg? Some insurance plans limit Mounjaro to specific doses based on cost negotiations. If your plan covers only up to 10 mg and your provider feels 15 mg is needed, an appeal with clinical documentation may open the higher dose. Check formulary specifics with your plan.

Sources

1. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
2. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155.
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
4. Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3). Lancet. 2021;398:583-598.
5. Del Prato S, et al. Tirzepatide versus insulin glargine (SURPASS-4). Lancet. 2021;398:1811-1824.
6. Dahl D, et al. Effect of tirzepatide vs placebo as add-on to titrated insulin glargine (SURPASS-5). JAMA. 2022;327:534-545.
7. FDA prescribing information, Mounjaro (tirzepatide), revised 2024.
8. FDA prescribing information, Zepbound (tirzepatide), revised 2024.
9. American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
10. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
11. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331:38-48.
12. Eli Lilly. Mounjaro Single-Dose Pen Instructions for Use, 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.